A Tufts Center for the Study of Drug Development White Paper

May 5, 2015

Biopharmaceutical drug development has been experiencing one of its most productive periods in recent history. During the past decade, the total number of new chemical and biologic entities in the R&D pipeline has been rising 6% each year and now exceeds 10,000 active drug candidates targeting unmet and under-served medical needs.

Spotlight

Bon Secours Health System

Bon Secours Health System, Inc. based in Marriottsville, Maryland, is a $3.2 billion dollar not-for-profit Catholic health system that owns, manages or joint ventures 18 acute care, 5 long term care, 4 assisted living, 6 retirement communities/senior housing, 14 home care and hospice services, and other facilities, primarily on the East Coast. Bon Secours Health System consists of more than 24,000 caregivers helping people in seven states. Its vision is to be a prophetic Catholic health ministry partnering with communities to create a more humane world, build health and social justice and provide exceptional value for those served.

OTHER WHITEPAPERS
news image

Non-Clinical Testing Considerations: Drugs vs Devices

whitePaper | November 8, 2022

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most important difference is that medical devices do not achieve their principal action by pharmacological means.

Read More
news image

Benefits of Semantic Enrichment Across the Drug Development Pipeline

whitePaper | January 24, 2022

Semantics is the process of assigning meaning to words and is a vital step in making unstructured scientific content machine readable, contextualizing otherwise unstructured information. It unlocks a host of benefits to search and analytics which are outlined below in the context of use cases relevant to drug discovery.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomes in Diabetes

whitePaper | July 21, 2022

The growing costs of the diabetes epidemic in the U.S. are staggering. Over 37 million Americans around 11% of the population now have diabetes, and according to a recent study, over 60 million Americans are expected to have the disease by 2060.

Read More
news image

The Ultimate Guide to Digitizing Pharma Manufacturing

whitePaper | September 15, 2022

The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.

Read More
news image

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

Read More

Spotlight

Bon Secours Health System

Bon Secours Health System, Inc. based in Marriottsville, Maryland, is a $3.2 billion dollar not-for-profit Catholic health system that owns, manages or joint ventures 18 acute care, 5 long term care, 4 assisted living, 6 retirement communities/senior housing, 14 home care and hospice services, and other facilities, primarily on the East Coast. Bon Secours Health System consists of more than 24,000 caregivers helping people in seven states. Its vision is to be a prophetic Catholic health ministry partnering with communities to create a more humane world, build health and social justice and provide exceptional value for those served.

Events